Cancer cell metabolism

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 76, Issue , 2011, Pages 299-311

  Cairns, R A ^a   Harris, I ^a,b   Mccracken, S ^a   Mak, T W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; DJ 1 PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN; ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OCTAMER TRANSCRIPTION FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SOMATOMEDIN C RECEPTOR; GLUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR; PROTEIN DEGLYCASE DJ-1; PROTEIN P53; PYRUVATE KINASE M2; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ADAPTATION; ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL METABOLISM; CELL SURVIVAL; CELLULAR DISTRIBUTION; CITRIC ACID CYCLE; DNA DAMAGE; FEEDBACK SYSTEM; GENE EXPRESSION; GENE SILENCING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; GLYCOSYLATION; HUMAN; INTRACELLULAR SIGNALING; LIPID METABOLISM; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SECOND MESSENGER; TUMOR MICROENVIRONMENT; UBIQUITINATION; AEROBIC GLYCOLYSIS; AMINO ACID METABOLISM; CELL HYPOXIA; OXIDATION REDUCTION STATE; SIGNAL TRANSDUCTION;

ANIMALS; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION;

EID: 84867422886     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2011.76.012856     Document Type: Article

References (166)

1. Aleyasin H, RousseauxMW, Marcogliese PC, Hewitt SJ, Irrcher I, Joselin AP, Parsanejad M, Kim RH, Rizzu P, Callaghan SM, et al. 2010. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci 107: 3186-3191.
2. Almeida R, Almeida J, ShoshkesM, Mendes N, MesquitaP, Silva E, Van Seuningen I, Reis CA, Santos-Silva F, David L. 2005. OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol 207: 396-401.
3. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG. 1997. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272: 217-221.
4. Bajaj A, Driver JA, Schernhammer ES. 2010. Parkinson's disease and cancer risk: A systematic review and meta-analysis. Cancer Causes Control 21: 697-707.
5. Bell EL, Emerling BM, Chandel NS. 2005. Mitochondrial regulation of oxygen sensing. Mitochondrion 5: 322-332.
6. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
7. Bertout JA, Patel SA, Simon MC. 2008. The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975.
8. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, et al. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
9. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Aktpromotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
10. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. 2004. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304: 596-600.
11. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, Carling D, Thompson CB, Jones RG, Berger SL. 2010. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329: 1201-1205.
12. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. 2005. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid b-oxidation. Oncogene 24: 4165-4173.
13. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
14. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517.
15. Chan EY. 2009. mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex. Sci Signal 2: e51.
16. ChenW, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD. 2009. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34: 663-673.
17. Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N. 2010. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 18: 592-604.
18. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. 2008. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370.
19. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12: 463-469.
20. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. 2008a. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
21. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008b. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186.
22. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. 2006. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci 103: 15091-15096.
23. Coles NW, Johnstone RM. 1962. Glutamine metabolism in Ehrlich ascites-carcinoma cells. Biochem J 83: 284-291.
24. Copeland NG, Jenkins NA. 2009. Deciphering the genetic landscape of cancer-From genes to pathways. Trends Genet 25: 455-462.
25. Czernin J, Phelps ME. 2002. Positron emission tomography scanning: Current and future applications. Annu Rev Med 53: 89-112.
26. Dai Y, Wolfgang MJ, Cha SH, Lane MD. 2007. Localization and effect of ectopic expression of CPT1c in CNS feeding centers. Biochem Biophys Res Commun 359: 469-474.
27. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
28. Dansen TB, Kops GJ, Denis S, Jelluma N, Wanders RJ, Bos JL, Burgering BM, Wirtz KW. 2004. Regulation of sterol carrier protein gene expression by the forkhead transcription factor FOXO3a. J Lipid Res 45: 81-88.
29. David CJ, Chen M, Assanah M, Canoll P, Manley JL. 2010. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
30. Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Florenes VA, Kopolovic J, Reich R. 2008. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 39: 87-95.
31. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci 104: 19345-19350.
32. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183.
33. Eagle H. 1955. Nutrition needs of mammalian cells in tissue culture. Science 122: 501-514.
34. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
35. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al. 2008. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27: 1932-1943.
36. Fan Y, Dickman KG, Zong WX. 2010. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285: 7324-7333.
37. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, Wang X. 2010. The ER UDPase ENTPD5 promotes protein Nglycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 143: 711-724.
38. Fantin VR, St-Pierre J, Leder P. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434.
39. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
40. Fruehauf JP, Meyskens FL Jr. 2007. Reactive oxygen species: A breath of life or death? Clin Cancer Res 13: 789-794.
41. Gambhir SS. 2002. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2: 683-693.
42. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. 2001. A tabulated summary of the FDG PET literature. J Nucl Med 42(5 Suppl): 1S-93S.
43. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, et al. 2007. HIFdependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238.
44. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
45. Garcia-Martinez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375-385.
46. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. 2006. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13: 1423-1433.
47. Gasser T, Muller-Myhsok B, Wszolek ZK, Durr A, Vaughan JR, Bonifati V, Meco G, Bereznai B, Oehlmann R, Agid Y, et al. 1997. Genetic complexity and Parkinson's disease. Science 277: 388-389; author reply 389.
48. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
49. Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. 2005. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 25: 6391-6403.
50. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2): 24S-42S.
51. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207: 339-344.
52. Gruning NM, Rinnerthaler M, Bluemlein K, Mulleder M, Wamelink MM, Lehrach H, Jakobs C, Breitenbach M, Ralser M. 2011. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab 14: 415-427.
53. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
54. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
55. Han D, Antunes F, Canali R, Rettori D, Cadenas E. 2003. Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 278: 5557-5563.
56. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
57. Hanahan D, Weinberg RA. 2010. Hallmarks of cancer: The next generation. Cell 144: 646-674.
58. Hay N. 2011. Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. doi:10.1016/j.bbamcr.2011.03.013.
59. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl KA. 2010. Transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17: 348-361.
60. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, et al. 2009. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 20: 1981-1991.
61. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al. 2010. International network of cancer genome projects. Nature 464: 993-998.
62. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. 2008. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27: 1919-1931.
63. Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
64. Inoki K, Corradetti MN, Guan KL. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
65. Jadvar H, Alavi A, Gambhir SS. 2009. 18F-FDG uptake in lung, breast, and colon cancers: Molecular biology correlates and disease characterization. J Nucl Med 50: 1820-1827.
66. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X. 2011. p53 Regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13: 310-316.
67. Jin T, Branch DR, Zhang X, Qi S, Youngson B, Goss PE. 1999. Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer 81: 104-112.
68. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. 2005. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
69. 2 sensing and cancer. Nat Rev Cancer 8: 865-873.
70. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH. 2009. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355.
71. Kapitsinou PP, Haase VH. 2008. The VHL tumor suppressor and HIF: Insights from genetic studies in mice. Cell Death Differ 15: 650-659.
72. Khatri S, Yepiskoposyan H, Gallo CA, Tandon P, Plas DR. 2010. FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem 285: 15960-15965.
73. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, et al. 2005a. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273.
74. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, et al. 2005b. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci 102: 5215-5220.
75. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. 2007. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27: 7381-7393.
76. Kim J, Kundu M, Viollet B, Guan KL. 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132-141.
77. King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682.
78. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. 1999. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634.
79. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM. 2002. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321.
80. Kriska T, Pilat A, Schmitt JC, Girotti AW. 2010. Sterol carrier protein-2 (SCP-2) involvement in cholesterol hydroperoxide cytotoxicity as revealed by SCP-2 inhibitor effects. J Lipid Res 51: 3174-3184.
81. Kuhajda FP. 2008. AMP-activated protein kinase and human cancer: Cancer metabolism revisited. Int J Obes (Lond) 32(Suppl 4): S36-S41.
82. Lane MD, Wolfgang M, Cha SH, Dai Y. 2008. Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond) 32(Suppl 4): S49-S54.
83. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV. 2010. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci 107: 2037-2042.
84. 2. J Biol Chem 277: 20336-20342.
85. Lehninger AL, Nelson DL, Cox MM. 1993. Principles of Biochemistry. Worth, New York.
86. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, et al. 2006. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125: 987-1001.
87. Li L, Qi Z, Qian J, Bi F, Lv J, Xu L, Zhang L, Chen H, Jia R. 2010. Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway. Mol Cell Biochem 342: 125-131.
88. Liu Y, Borchert GL, Donald SP, Surazynski A, Hu CA, Weydert CJ, Oberley LW, Phang JM. 2005. MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis 26: 1335-1342.
89. Liu Y, Borchert GL, Surazynski A, Phang JM. 2008. Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 27: 6729-6737.
90. Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM. 2009. Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res 69: 6414-6422.
91. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, et al. 2011. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874.
92. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. 2008. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283: 28106-28114.
93. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744.
94. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med 361: 1058-1066.
95. Mathupala SP, Heese C, Pedersen PL. 1997. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272: 22776-22780.
96. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. 2006. p53 Regulates mitochondrial respiration. Science 312: 1650-1653.
97. Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, You H. 2009. FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc Natl Acad Sci 106: 5153-5158.
98. Menendez JA, Lupu R. 2007. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
99. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. 1997. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231: 509-513.
100. Nathan C, Ding A. 2010. SnapShot: Reactive oxygen intermediates (ROI). Cell 140: 951, e2-952.e2.
101. Nemoto S, Finkel T. 2002. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-2452.
102. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N. 2008. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14: 458-470.
103. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. 2010. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140: 49-61.
104. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29: 541-551.
105. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. 2006. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197.
106. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
107. Plas DR, Thompson CB. 2005. Akt-dependent transformation: There is more to growth than just surviving. Oncogene 24: 7435-7442.
108. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo H-K, Jang HG, Jha AK, et al. 2011. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476: 346-350.
109. Pouyssegur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
110. Ramsey MR, Sharpless NE. 2006. ROS as a tumour suppressor? Nat Cell Biol 8: 1213-1215.
111. Reamy AA, Wolfgang MJ. 2011. Carnitine palmitoyltransferase-1c gain-of-function in the brain results in postnatal microencephaly. J Neurochem 118: 388-398.
112. Reitzer LJ, Wice BM, Kennell D. 1979. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669-2676.
113. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. 2010. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 49: 1603-1616.
114. Robey RB, Hay N. 2009. Is Akt the "Warburg kinase"? Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19: 25-31.
115. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, et al. 2006. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55: 2042-2050.
116. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
117. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113.
118. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. 2004. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64: 2627-2633.
119. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7: 77-85.
120. Semenza GL. 2010. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
121. Shackelford DB, Shaw RJ. 2009. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
122. Shakya A, Cooksey R, Cox JE, Wang V, McClain DA, Tantin D. 2009. Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol 11: 320-327.
123. Sierra AY, Gratacos E, Carrasco P, Clotet J, Urena J, Serra D, Asins G, Hegardt FG, Casals N. 2008. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem 283: 6878-6885.
124. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, et al. 2008. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930-3942.
125. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, et al. 2011. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci 108: 4129-4134.
126. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. 1995. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296-299.
127. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. 2010. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci 107: 7461-7466.
128. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E. 2006. Mitogenic signalling and the p16INK4a-Rb pathwaycooperate to enforce irreversible cellular senescence. Nat Cell Biol 8: 1291-1297.
129. Tennant DA, Duran RV, Gottlieb E. 2010. Targeting metabolic transformationfor cancer therapy. NatRevCancer 10: 267-277.
130. Tong X, Zhao F, Thompson CB. 2009. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19: 32-37.
131. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128: 325-339.
132. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, et al. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
133. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, et al. 2008. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112: 1912-1922.
134. Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.
135. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. 2006. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
136. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
137. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, et al. 2010. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329: 1492-1499.
138. Vaughn AE, Deshmukh M. 2008. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 10: 1477-1483.
139. Vousden KH. 2009. Functions of p53 in metabolism and invasion. Biochem Soc Trans 37(Pt 3): 511-517.
140. Warburg O. 1956a. On respiratory impairment in cancer cells. Science 124: 269-270.
141. Warburg O. 1956b. On the origin of cancer cells. Science 123: 309-314.
142. Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body. J Gen Physiol 8: 519-530.
143. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, HedvatCV, Perl AE, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
144. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. 2008. Forkhead box-O transcription factor: Critical conductors of cancer's fate. Endocr Relat Cancer 15: 917-929.
145. Weinberg F, Hamanaka R, WheatonWW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2011. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci 107: 8788-8793.
146. Weinhouse S. 1976. Regulation of glucokinase in liver. Curr Top Cell Regul 11: 1-50.
147. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, Thompson CB. 2011. The hexosamine biosynthetic pathway couples growth factorinduced glutamine uptake to glucose metabolism. Genes Dev 24: 2784-2799.
148. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci 105: 18782-18787.
149. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. 2011. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208: 313-326.
150. Wolfgang MJ, Lane MD. 2006. The role of hypothalamic malonyl-CoA in energy homeostasis. J Biol Chem 281: 37265-37269.
151. Wolfgang MJ, Lane MD. 2011. Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. FEBS J 278: 552-558.
152. Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto S, Cha SH, Shimokawa T, Lane MD. 2006. The brainspecific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci 103: 7282-7287.
153. Wolfgang MJ, Cha SH, Millington DS, Cline G, Shulman GI, Suwa A, Asaumi M, Kurama T, Shimokawa T, Lane MD. 2008. Brain-specific carnitine palmitoyl-transferase-1c: Role in CNS fatty acid metabolism, food intake, and body weight. J Neurochem 105: 1550-1559.
154. Wong KK, Engelman JA, Cantley LC. 2010. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90.
155. Wouters BG, Koritzinsky M. 2008. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864.
156. XuW, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
157. Yan H, ParsonsDW, Jin G, McLendon R, Rasheed BA, YuanW, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. New Engl J Med 360: 765-773.
158. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. 2009. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69: 7986-7993.
159. Yecies JL, Manning BD. 2011. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89: 221-228.
160. Yoon KA, Nakamura Y, Arakawa H. 2004. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 49: 134-140.
161. Yuen HF, Chan YP, Law S, Srivastava G, El-Tanani M, Mak TW, Chan KW. 2008. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17: 3593-3602.
162. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, et al. 2011. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25: 1041-1051.
163. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, et al. 2006. FoxO1 regulates multiple metabolic pathways in the liver: Effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 281: 10105-10117.
164. Zhang HH, Huang J, Duvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD. 2009. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 4: e6189.
165. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324: 261-265.
166. Zoncu R, Efeyan A, Sabatini DM. 2010. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.